1
William G Tatton: Deprenyl compounds for treatment of glaucoma. The University of Toronto Innovations Foundation, Lahive & Cockfield, November 9, 1999: US05981598 (48 worldwide citation)

Methods and kits for treament of glaucoma are disclosed. In general, the methods of the invention include administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.


2
William G Tatton, Carol E Greenwood: Use of deprenyl to rescue damaged nerve cells. University of Toronto Innovations Foundation, Lahive & Cockfield, August 22, 1995: US05444095 (17 worldwide citation)

The present invention relates to the use of deprenyl or derivatives or analogues of deprenyl to rescue damaged nerve cells in an animal; to pharmaceutical compositions containing deprenyl adapted for such use; and, to methods for the treatment of disorders of the nervous system by rescuing damaged n ...


3
William G Tatton, Carol E Greenwood: Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function. Innovations Foundation, Elizabeth A Hanley, Mark D Lahive & Cockfield Russett, December 1, 1998: US05844003 (14 worldwide citation)

The present invention relates to the use of deprenyl compounds to rescue damaged nerve cells in a patient and to kits containing deprenyl compounds useful for rescuing damaged nerve cells in a patient.


4
L Sai Latha Shankar, William G Tatton, Nadine A Tatton: Methods for treating multiple sclerosis. Elizabeth A Hanley, Merideth C Arnold, Lahive & Cockfield, December 10, 2002: US06492427 (7 worldwide citation)

Methods for increasing oligodendrocyte survival are disclosed. The methods of the invention are useful for the treatment of Multiple Sclerosis.


5
William G Tatton, Carol E Greenwood: Use of deprenyl to rescue damaged nerve cells. Innovations Foundation, Elizabeth A Hanley, Mark D Lahive & Cockfield Russett, June 16, 1998: US05767164 (6 worldwide citation)

The present invention relates to the use of deprenyl or derivatives or analogues of deprenyl to rescue damaged nerve cells in an animal; to pharmaceutical compositions containing deprenyl adapted for such use; and, to methods for the treatment of disorders of the nervous system by rescuing damaged n ...


6
Nadine A Tatton, William G Tatton: Methods for increasing schwann cell survival. Elizabeth A Hanley, Lahive & Cockfield, July 9, 2002: US06417160 (5 worldwide citation)

Methods for increasing Schwann cell survival are disclosed. The methods of the invention are useful for the treatment of conditions such as peripheral neuropathies, including diabetic neuropathies.


7
William G Tatton: Deprenyl compounds for treatment of glaucoma. The University of Toronto Innovations Foundation, Lahive & Cockfield, July 21, 1998: US05783606 (5 worldwide citation)

Methods and kits for treatment of glaucoma are disclosed. In general, the methods of the invention include administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.


8
William G Tatton: Deprenyl compounds for treatment of glaucoma. University of Toronto Innovations Foundation, Lahive & Cockfield, September 24, 2002: US06455590 (1 worldwide citation)

Methods and kits for treament of glaucoma are disclosed. In general, the methods of the invention include administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.


9
Nadine A Tatton, William G Tatton: Methods for increasing schwann cell survival. Lahive and Cockfield, Elizabeth A Hanley Esq, Cynthia M Soroos Esq, January 9, 2007: US07160857

Methods for increasing Schwann cell survival are disclosed. The methods of the invention are useful for the treatment of conditions such as peripheral neuropathies, including diabetic neuropathies.


10
William G Tatton, Katherine Borden: Dehydrogenase oligomeric modulators. Lahive & Cockfield, May 6, 2004: US20040086891-A1

Methods of screening compounds which are oligomeric modulators of dehydrogenases such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and such oligomeric modulators. In one aspect, methods are presented for identifying an oligomeric modulator of a dehydrogenase, comprising contacting the dehydr ...